Companies Cryptocurrencies
Strongbridge Biopharma plc
Strongbridge Biopharma plc
Exchange: Nasdaq Global Select
IPO Date: 10/09/2015
CEO: Mr. Matthew Pauls
Biotechnology Healthcare 🔗
  • SBBP
  • 2.14
  • 145154064
    market cap
  • 0.05000019
If you bought

shares of Strongbridge Biopharma plc (SBBP) on
You would have made
Old Price $12 Current Price $12

Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. The company is headquartered in Trevose, Pennsylvania and currently employs 106 full-time employees. The firm is focused on the development and commercialization of therapies for a range of diseases. The firm’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The firm has a clinical-stage pipeline of therapies for endocrine diseases. The firm’s lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The firm is studying COR-003 for the treatment of endogenous Cushing’s syndrome. The company is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).

Address: 900 Northbrook Dr Ste 200 Trevose PENNSYLVANIA

Stay updated.